Ex-Lab21 exec Hayden Jeffreys joins Lumora
This article was originally published in Clinica
UK molecular diagnostics specialist Lumora has appointed Hayden Jeffreys, previously of personalised medicine firm Lab21, as commercial director as it aims to expand its portfolio of products and licences. Mr Jeffreys was divisional director of Lab21's diagnostics products unit for over four years; before this, he was commercial director of Invitron (from 2006 until 2008) and business development manager at molecular diagnostics firm Gen-Probe (from 2003 until 2005), which was acquired by Hologic last year (www.clinica.co.uk, 1 May 2012). Ely-based Lumora has developed a platform called BART (bioluminescent assay in real-time), which it describes as "the simplest ever system for molecular diagnostics", and believes could make molecular testing more affordable and therefore increase its uptake. Lumora has already licensed the technology to 3M for food and beverage testing, and believes the appointment of Mr Jeffreys will help it exploit opportunities in the medical sector. Lumora has a portfolio of medical tests, including one for Clostridium difficile, which "are in various stages of development including evaluation and licensing discussions", the company told Clinica.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.